Humans Mitomycin/therapeutic use Antibiotics Antineoplastic BCG Vaccine/therapeutic use *Non-Muscle Invasive Bladder Neoplasms Neoplasm Recurrence Local/drug therapy *Urinary Bladder Neoplasms/pathology Administration Intravesical Neoplasm Invasiveness Bladder cancer Device-assisted Emda Intravesical drug administration Nmibc

detrusor muscle en bloc resection of bladder tumor non-muscle invasive bladder cancer

Bacillus Calmette-Guérin Chemoablation Epirubicin Gemcitabine Intravesical therapy Mitomycin Non–muscle-invasive bladder cancer

Data Systems Humans Magnetic Resonance Imaging/methods *Multiparametric Magnetic Resonance Imaging Reproducibility of Results Urinary Bladder/diagnostic imaging/pathology *Urinary Bladder Neoplasms/diagnostic imaging/surgery Bladder cancer Bladder cancer staging Multiparametric magnetic resonance imaging Muscle-invasive bladder cancer conflict of interest to disclose.

Administration Intravesical Combined Modality Therapy Cystectomy/*methods Humans Neoplasm Recurrence Local/*epidemiology Network Meta-Analysis Randomized Controlled Trials as Topic Urethra Urinary Bladder Neoplasms/*diagnostic imaging/drug therapy/epidemiology/*surgery #BladderCancer #blcsm #uroonc blue-light cystoscopy hexaminolevulinic acid narrow band imaging non-muscle-invasive urothelial carcinoma photodynamic diagnosis single immediate intravesical chemotherapy

Cisplatin/adverse effects Humans *Immunotherapy/adverse effects/methods *Muscles/pathology *Neoadjuvant Therapy/adverse effects Neoplasm Staging *Urinary Bladder Neoplasms/drug therapy/pathology/therapy chemoimmunotherapy immunotherapy meta-analysis muscle-invasive bladder cancer (MIBC) neoadjuvant commercial or financial relationships that could be construed as a potential conflict of interest.

Humans *Urinary Bladder Neoplasms/surgery/pathology Neoplasm Recurrence Local/pathology Cystectomy/methods Cystoscopy/methods Light #BladderCancer #blcsm #uroonc blue light non-muscle-invasive bladder cancer photodynamic diagnosis transurethral resection of the bladder white light

Humans Magnetic Resonance Imaging *Multiparametric Magnetic Resonance Imaging Muscles Prospective Studies Urinary Bladder *Urinary Bladder Neoplasms/diagnostic imaging Bladder cancer Meta-analysis Muscle invasion Vesical imaging-reporting and data system

Bcg Bacillus Calmette–Guérin Nmibc bladder cancer checkpoint inhibition therapy nadofaragene firadenovec non muscle invasive oncolytic viruses

Female Gene Expression Profiling Gene Regulatory Networks Humans Male Muscles Neoplasm Invasiveness Prognosis *Urinary Bladder Neoplasms/genetics/metabolism rab GTP-Binding Proteins/genetics/metabolism Bladder cancer Gene expression Muscle-invasive bladder cancer Urothelial cancer

Artificial Intelligence Humans Muscles/pathology ROC Curve Sensitivity and Specificity *Urinary Bladder Neoplasms/diagnostic imaging/pathology Bladder cancer Meta-analysis Muscle invasive Radiomics Staging Systematic review

adjuvant immune checkpoint inhibitors muscle-invasive bladder cancer neoadjuvant

Cystectomy/*methods Electrosurgery/*methods Humans Neoplasm Invasiveness Urethra Urinary Bladder Neoplasms/pathology/*surgery Bipolar Meta-analysis Monopolar Non-muscle invasive bladder cancer Transurethral resection

fluorescence in situ hybridization meta-analysis non-muscle invasive bladder cancer surveillance needs to disclose.

Catheterization time Conventional transurethral resection Cáncer vesical primario no músculo-infltrante Duración de la estancia hospitalaria En-bloc transurethral resection Length of hospital stay Primary non-muscle invasive bladder cancer Recurrence Recurrencia Resección transuretral convencional Resección transuretral en bloque Tiempo de sondaje

Humans Male *Urinary Bladder Neoplasms Reproducibility of Results ROC Curve Image Interpretation Computer-Assisted Muscles Magnetic Resonance Imaging Retrospective Studies Bladder cancer Inter-reader agreement Meta-analysis Reliability Vi-rads

Administration Intravesical *Carcinoma Transitional Cell/pathology Epirubicin/therapeutic use Female Humans Male Mitomycin/therapeutic use Neoplasm Recurrence Local Randomized Controlled Trials as Topic *Urinary Bladder Neoplasms/pathology Intravesical Chemotherapy Non-muscle Invasive Bladder Cancer Turb

*Carcinoma Transitional Cell/pathology Female Humans Male Neoplasm Invasiveness Nephroureterectomy Sweden *Urinary Bladder Neoplasms/pathology Swedish national guidelines Urothelial carcinoma non-muscle invasive bladder cancer upper tract urothelial carcinoma

Antineoplastic Combined Chemotherapy Protocols/therapeutic use *Carcinoma Transitional Cell/pathology Cisplatin/therapeutic use Cystectomy Humans Muscles/pathology Neoadjuvant Therapy Neoplasm Invasiveness *Urinary Bladder Neoplasms/pathology Bladder cancer Muscle-invasive Urothelial from MSD and BMS and Speaker and Other from AstraZecena. BPV reports Advisory Board Speaker and Other from Astellas Roche BMS and Merk-Pfizer Advisory Board and Other from Ipsen Advisory Board and Speaker from EUSA and MSD and Advisory Board from Sanofi. IPF report Advisory Board Speaker and Other from Pfizer Speaker and Other from Ipsen and Roche Advisory Board from EUSA and BMS and Speaker from Novartis and MSD. OFC reports Advisory Board and Speaker from Ipsen and Astellas Advisory Board from BMS and Pfizer-Merck and Speaker from AstraZeneca. AGA has received research funding from Astellas travel grants from Astellas Jansen Sanofi BMS Roche Pfizer and Ipsen and honoraria for speaker engagements advisory boards and continuous medical education from Janssen Astellas Sanofi Bayer Roche Ipsen BMS MSD Pfizer Eusa Pharma Eisai and AstraZeneca. JAA reports honoraria from Astellas Pfizer and BMS conulting or advisory role from Pfizer Astellas Janssen-Cilag MSD Oncology BMS Merck AstraZeneca Bayer and Eisai and Research Funding from BMS. RMB SVE CCD and MDS have nothing to disclose.

#BladderCancer #blcsm #uroonc cystoscopy gross appearance multiplicity non-muscle-invasive bladder cancer progression recurrence size